SCHEMBL6892792

SCHEMBL6892792

CC(I)OC(=O)Oc1cccc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
HSD17B10 Q99714 3/20 0.54
PGR P06401 1/20 0.54
GAA P10253 1/20 0.54
PTGS1 P23219 1/20 0.54
MAPK1 P28482 1/20 0.54
KMT2A Q03164 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
RAB9A P51151 2/20 0.49
MEN1 O00255 1/20 0.49
KDM4E B2RXH2 3/20 0.47
HPGD P15428 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
MMP2 P08253 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
FABP7 O15540 4/20 0.43
FABP3 P05413 4/20 0.43
FABP5 Q01469 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28379570 0.87 ALDH1A1 (0.57) ALDH1A1HSD17B10PGRGAAPTGS1
SCHEMBL1598809 0.82 HSD17B10 (0.67) ALDH1A1HSD17B10PGRGAAPTGS1
SCHEMBL29525161 0.82 HSD17B10 (0.67) ALDH1A1HSD17B10PGRGAAPTGS1
SCHEMBL29901836 0.81 ALDH1A1 (0.65) ALDH1A1HSD17B10PGRGAAPTGS1
SCHEMBL37865 0.81 ALDH1A1 (0.65) ALDH1A1HSD17B10PGRGAAPTGS1
SCHEMBL28399465 0.80 ALDH1A1 (0.54) ALDH1A1HSD17B10PGRGAAPTGS1
SCHEMBL28699574 0.79 ALDH1A1 (0.48) ALDH1A1HSD17B10PGRGAAPTGS1
SCHEMBL6893509 0.79 KMT2A (0.49) ALDH1A1HSD17B10KMT2AL3MBTL1MEN1
SCHEMBL6892954 0.79 TDP1 (0.44) ALDH1A1HSD17B10L3MBTL1KDM4EHPGD
SCHEMBL10954512 0.78 KMT2A (0.64) ALDH1A1HSD17B10PGRGAAPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 ALDH1A1 1161/4885HSD17B10 339/4885PGR 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.